Dennis Lowenthal, MD
Medical Oncology · Summit, NJNPI 1528050374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $849 and has fallen 66.9% since, to $281 in 2025. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.
Across 146 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$252
- Novartis$240
- Merck$192
- Amgen$178
- Johnson & Johnson$145
- Astellas Pharma US Inc$142
- plus $1K from 37 others
Across 54 payments — averaging $3813.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$132K
- Genentech, Inc.$70K
- Astrazeneca UK Limited$3K
- Pharmacyclics LLC, An Abbvie Company$1K
- AstraZeneca$932
What the payments were for
- Food & beverage$2,31995%
- Education$1345%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,453 in reported general payments places this provider in the 50th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 22 | $406,461 |
| CalquenceAcalabrutinib Maleate | 22 | $337,559 |
| Lenalidomide | 22 | $302,759 |
| RevlimidLenalidomide | 11 | $198,890 |
| ImbruvicaIbrutinib | 11 | $181,469 |
| TabrectaCapmatinib Hydrochloride | 14 | $158,880 |
| XalkoriCrizotinib | 11 | $122,806 |
| XareltoRivaroxaban | 36 | $22,145 |
| Hydroxyurea | 16 | $1,032 |
| Prochlorperazine Maleate | 12 | $93 |
| Warfarin Sodium | 22 | $73 |
| Ondansetron Hcl | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $29 | $406,46122 claims |
| AstraZenecaCalquence | $78 | $337,55922 claims |
| Bristol Myers SquibbRevlimid | $60 | $198,89011 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $31 | $181,46911 claims |
| NovartisTabrecta | $240 | $158,88014 claims |
| Johnson & JohnsonXarelto | $145 | $22,14536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Summit
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.